Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Mipletamig · APVO-436

Bispecific antibody · Immune activation, directed at CD123 (interleukin-3 receptor alpha chain) (IL3RA) and CD3 (CD3E) · developed by Aptevo Therapeutics

Phase 1 Most advanced trial

APVO Developer

1 Registered trials

What is Mipletamig?

Mipletamig is an Fc-modified bispecific antibody that binds CD123 on cancer cells and CD3 on T-cells, crosslinking the two cell types. This activates and expands T-cells and drives cytotoxic T-lymphocyte killing of CD123-expressing tumor cells. It is studied in acute myeloid leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: APVO-436
Drug type: Bispecific antibody
Targets: CD123 (interleukin-3 receptor alpha chain) (IL3RA), CD3 (CD3E)
Mechanism: Immune activation, directed at CD123 (interleukin-3 receptor alpha chain) (IL3RA) and CD3 (CD3E)
Pathways: T-cell activation and proliferation, CTL-mediated lysis of tumor cells
Therapy area: Oncology
Developer: Aptevo Therapeutics (APVO)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1
UNII: DNP8BBW84R

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06634394	Phase 1	Acute Myeloid Leukemia (AML)	Recruiting	APVO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Myeloid Leukemia (AML)

Other drugs acting on IL3RA / CD3E

Anti-Thymocyte Globulin FDA approved Blinatumomab FDA approved Pivekimab Sunirine FDA approved AZD5492 Phase 1/2 CT-95 Phase 1 Foralumab Phase 2 Gocatamig Phase 1/2 Imvotamab Phase 1/2 MK-1045 Phase 2/3 Odronextamab Phase 2/3 TAK-186 Phase 1/2

More from Aptevo Therapeutics

ALG.APV-527 Phase 1/2 APVO210 Phase 1 ES414 Phase 1 Otlertuzumab Phase 1/2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the APVO page.

Follow APVO, the company behind Mipletamig

See APVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

APVO catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z